Aprepitant as an add-on therapy in children receiving highly emetogenic chemotherapy: a randomized, double-blind, placebo-controlled trial

@article{Bakhshi2015AprepitantAA,
  title={Aprepitant as an add-on therapy in children receiving highly emetogenic chemotherapy: a randomized, double-blind, placebo-controlled trial},
  author={Sameer Bakhshi and Atul Batra and Bivas Biswas and Deepa Dhawan and Reeja Paul and V. Sreenivas},
  journal={Supportive Care in Cancer},
  year={2015},
  volume={23},
  pages={3229-3237}
}
Aprepitant, a neurokinin-1 receptor antagonist, in combination with 5 HT-3 antagonist and dexamethasone is recommended in adults receiving moderately and highly emetogenic chemotherapy to reduce chemotherapy-induced vomiting (CIV). Data for use of aprepitant in children is limited and hence aprepitant is not recommended by Pediatric Oncology Group of Ontario guidelines for prevention of CIV in children <12 years. A randomized, double-blind, placebo-controlled trial was conducted at a single… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

References

Publications referenced by this paper.
Showing 1-10 of 23 references

a systematic review

  • LV dos Santos, FH Souza, AT Brunetto, AD Sasse, nausea da Silveira Nogueira Lima JP Neurokinin-1 receptor chemotherapy-induced, vomiting
  • J Natl Cancer Inst 104(17):1280–1292 Support…
  • 2015
1 Excerpt

Similar Papers

Loading similar papers…